Our findings highlight the potential clinical utility of BA in combination with EGFR-TKIs in wt-EGFR lung cancer, suggesting that targeting the EGFR-mediated autophagic pathway remains a viable therapeutic strategy to overcome primary resistance to EGFR-TKIs in wt-EGFR NSCLC. Here, EGFR is linked to lung cancer.